About: Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)
Creator	Ducancelle, Alexandra Lefeuvre, Caroline Joubaud, Françoise Le Guillou-Guillemette, Hélène Le, Hélène Lunel-Fabiani, Françoise Nicol, Thomas Pharmd, Guillou-Guillemette Pivert, Adeline Serri, Orianne
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: The emergence of new SARS-CoV-2 has promoted the development of new serological tests that could be complementary to RT-PCR. Nevertheless, the assessment of clinical performances of available tests is urgently required as their use has just been initiated for diagnose. OBJECTIVES: The aim of this study was to assess the performance of three immunoassays for the detection of SARS-CoV-2 antibodies. METHODS: Two automated immunoassays (Abbott SARS-CoV-2 CLIA IgG and Euroimmun Anti-SARS-CoV-2 ELISA IgG/IgA assays) and one lateral flow immunoassay (LFIA NG-Test® IgG-IgM COVID-19) were tested. 293 specimens were analyzed from patients with a positive RT-PCR response, from patients with symptoms consistent with COVID-19 but exhibiting a negative response to the RT-PCR detection test, and from control group specimens. Days since symptoms onset were collected from clinical information sheet associated with respiratory tract samples. RESULTS: Overall sensitivity for IgG was equivalent (around 80%) for CLIA, ELISA and LFIA. Sensitivity for IgG detection, >14 days after onset of symptoms, was 100.0% for all assays. Overall specificity for IgG was greater for CLIA and LFIA (more than 98%) compared to ELISA (95.8%). Specificity was significantly different between IgA ELISA (78.9%) and IgM LFIA (95.8%) (p < 0.05). The best agreement was observed between CLIA and LFIA assays (97%; k = 0.936). CONCLUSION: Excellent sensitivity for IgG detection was obtained >14 days after onset of symptoms for all immunoassays. Specificity was also excellent for IgG CLIA and IgG LFIA. Our study shows that NG-Test® is reliable and accurate for routine use in clinical laboratories.
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104511
bibo:pmid	32593133
has license	no-cc
sha1sum (hex)	b21e80ecd7611450ddab13836825ed1dd412cd9a
schema:url	https://doi.org/10.1016/j.jcv.2020.104511
resource representing a document's title	Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)
has PubMed Central identifier	PMC7295485
has PubMed identifier	32593133
schema:publication	J Clin Virol
resource representing a document's body	covid:b21e80ecd7611450ddab13836825ed1dd412cd9a#body_text
is schema:about of	named entity 'rapid' named entity 'immunoassays' named entity 'diagnosis' named entity 'Title' named entity 'ABSTRACT' named entity 'COUNT' named entity 'TELEPHONE NUMBER' named entity 'Title' named entity 'Word count' named entity 'Telephone number' named entity 'serological tests' named entity 'lateral flow immunoassay' named entity 'SARS-CoV-2' named entity 'European Commission' named entity 'IgM' named entity 'symptom' named entity 'SARS-CoV-2' named entity 'PCR testing' named entity 'CLIA' named entity 'viral load' named entity 'recombinant' named entity 'serological tests' named entity 'IgA' named entity 'significant difference' named entity 'symptom' named entity 'IgM' named entity 'IgG' named entity 'immunoassays' named entity 'IgM' named entity 'IgG' named entity 'IgG/IgM' named entity 'spike protein' named entity 'IgA' named entity 'IgM antibodies' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'CLIA' named entity 'COVID-19' named entity 'IgM' named entity 'Spain' named entity '95%' named entity 'RT-PCR' named entity 'respiratory tract' named entity 'IgM' named entity 'Wuhan' named entity 'CLIA' named entity 'viruses' named entity 'COVID' named entity 'IgG antibodies' named entity 'IgM' named entity 'cross-reaction' named entity 'Chicago' named entity 'structural protein' named entity 'seroprevalence' named entity 'IgG' named entity 'infection' named entity 'IgM' named entity 'morbidity' named entity 'RT-PCR' named entity 'real number' named entity 'public health' named entity 'IgM' named entity 'seroconversion' named entity 'point-of-care' named entity 'lateral flow' named entity 'serum samples' named entity 'immunoassays' named entity 'clinical laboratories' named entity 'epidemiologic studies' named entity 'seroprevalence' named entity 'CLIA' named entity 'sensitivity and specificity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software